We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cardiff Oncology Inc | NASDAQ:CRDF | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.58 | 3.39 | 3.69 | 15 | 09:00:00 |
Delaware |
001-35558
|
27-2004382 | ||||||
(State or other jurisdiction |
(Commission File Number)
|
IRS Employer | ||||||
of incorporation or organization) | Identification No.) |
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
||||||||||
Common Stock
|
|
CRDF
|
|
Nasdaq Capital Market
|
Directors
|
For
|
Against
|
Abstain
|
Broker Non Vote
|
|||||||||||||||||||||||||
Mark Erlander, Ph.D.
|
17,466,428
|
0
|
93,848
|
6,402,759
|
|||||||||||||||||||||||||
Dr. Rodney Markin
|
17,379,617
|
0
|
180,659
|
6,402,759
|
|||||||||||||||||||||||||
John Brancaccio
|
15,443,929
|
0
|
2,116,347
|
6,402,759
|
|||||||||||||||||||||||||
Dr. James O. Armitage
|
17,056,138
|
0
|
504,138
|
6,402,759
|
|||||||||||||||||||||||||
Lale White
|
17,470,056
|
0
|
90,220
|
6,402,759
|
|||||||||||||||||||||||||
Gary W. Pace, Ph.D.
|
16,507,384
|
0
|
1,052,892
|
6,402,759
|
|||||||||||||||||||||||||
Mani Mohindru, Ph.D.
|
16,496,539
|
0
|
1,063,737
|
6,402,759
|
|||||||||||||||||||||||||
Renee P. Tannenbaum, Pharm.D.
|
17,055,415
|
0
|
504,861
|
6,402,759
|
For
|
Against
|
Abstain
|
Broker Non Vote
|
||||||||||||||
23,370,409
|
503,514
|
89,112
|
0
|
For
|
Against
|
Abstain
|
Broker Non Vote
|
||||||||||||||
16,706,252
|
810,501
|
43,523
|
6,402,759
|
CARDIFF ONCOLOGY, INC. | ||||||||
By: | /s/ Mark Erlander | |||||||
Mark Erlander | ||||||||
Chief Executive Officer |
1 Year Cardiff Oncology Chart |
1 Month Cardiff Oncology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions